KYTX Live signals | Maximize Profits with Getagraph.com

SELL 115699 min ago

@ $30.42

Issued: 14 Feb 2024 @ 09:30

Return: -49.87%

Previous signal: Feb 13 - 09:30

Previous signal: Buy

Return: 4.14 %

Live Chart Being Loaded With Signals

Commentary (3 May 2024 @ 16:00):

Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases...

Stats
Today's Volume	459 143
Average Volume	409 925
Market Cap	657.51M
Next earnings date	( $0 ) 2024-06-25
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	0
ATR14	$0.0320 (0.21%)

Insider Trading

Date	Person	Action	Amount	type
2024-02-12	Gilead Sciences, Inc.	Buy	910 000	Common Stock
2024-02-12	Gilead Sciences, Inc.	Buy	3 216 119	Common Stock
2024-02-12	Gilead Sciences, Inc.	Sell	6 890 744	Series A-2 Convertible Preferred Stock
2024-02-12	Gilead Sciences, Inc.	Sell	7 746 139	Series B Convertible Preferred Stock
2024-02-07	Clark Ian T	Sell	38 736	Stock Option (Right to Buy)

INSIDER POWER
-64.72
Last 14 transactions
Buy: 4 126 119 \| Sell: 19 332 379

Volume Correlation

Long: 0.26 (neutral)

Short: -0.21 (neutral)

Signal:(62.385) Neutral

Kyverna Therapeutics, Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Kyverna Therapeutics, Correlation - Currency/Commodity

0.19
( neutral )

0.31
( neutral )

0.00
( neutral )

0.04
( neutral )

-0.58
( weak negative )

0.04
( neutral )

Financial Reports:

No articles found.

Kyverna Therapeutics,

Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial. The company is also developing KYV-201, an allogeneic CD19 CAR T-cell product candidate that is in preclinical stage to treat multiple autoimmune diseases. In addition, it is developing product candidates to treat other autoimmune diseases, such as inflammatory bowel disease that includes Crohn's disease and ulcerative colitis. Kyverna Therapeutics, Inc. has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product; and with Kite to research and develop programs for the treatment, diagnosis, and prevention of autoimmune, inflammatory, and allogeneic stem cell transplant inflammatory diseases. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.